DC-CIK联合化疗对结直肠癌根治术后患者疗效、免疫功能及生活质量的影响

DC-CIK combined with chemotherapy on the efficacy, immune function, and life quality in colorectal cancer patients after radical resection.

作者信息

Lu Dan, Li Ting, Yang Zhiqian, Zhao Xin, Su Yingying, Nian Liang

机构信息

Department of Anorectal, Xianyang First People's Hospital No. 10 Biyuan Road, Qindu District, Xianyang 712000, Shaanxi, China.

Tumor Diagnosis and Treatment Center, The First Hospital of Yulin No. 93 Yuxi Avenue, High Tech Zone, Yuyang District, Yulin 719000, Shaanxi, China.

出版信息

Am J Transl Res. 2023 Apr 15;15(4):2793-2801. eCollection 2023.

PMID:37193178

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10182484/

Abstract

OBJECTIVE

To investigate the efficacy of combined treatment of dendritic cell-cytokine-induced killer cells (DC-CIK) and chemotherapy on colorectal cancer (CRC) patients who have undergone radical resection, and its effect on immune function and quality of life.

METHODS

Data of 103 CRC patients after radical resection admitted to Xianyang First People's Hospital and Yanan University Affiliated Hospital from March 2018 to March 2020 were retrospectively analyzed. A total of 50 patients treated with XELOX chemotherapy were included in the control group (CG). The remaining 53 patients treated with XELOX chemotherapy combined with DC-CIK were included in the observation group (OG). The therapeutic efficacy, immune function indicators, serum tumor markers before and after the treatment, adverse reactions, 2-year survival rate, and quality of life 6 months after the treatment were observed and compared between the two groups.

RESULTS

The OG was identified to have a better therapeutic effect than the CG (P<0.05). After the treatment, the OG was assessed with significantly higher levels of IgG, IgA, and IgM than the CG. The CEA, CA724, and CA199 levels in the OG were significantly lower than those in the CG after the treatment (P<0.05). No significant difference was identified regarding the incidence of adverse reactions between the two groups (P>0.05). The quality of life six months after the treatment and the 2-year survival rate in the OG were significantly higher than those in the CG (P<0.05). The logistic regression analysis showed that pathological stage, differentiation, and treatment regimen were independent risk factors for poor prognosis (P<0.05).

CONCLUSION

DC-CIK combined with chemotherapy can improve the clinical efficacy, immune function, and long-term survival rate of CRC patients who have undergone radical resection. This combined regimen shows safety and is worthy of promotion in clinical practice.

摘要

目的

探讨树突状细胞-细胞因子诱导的杀伤细胞（DC-CIK）联合化疗对接受根治性切除的结直肠癌（CRC）患者的疗效，及其对免疫功能和生活质量的影响。

方法

回顾性分析2018年3月至2020年3月在咸阳市第一人民医院和延安大学附属医院收治的103例接受根治性切除的CRC患者的数据。对照组（CG）纳入50例接受XELOX化疗的患者。其余53例接受XELOX化疗联合DC-CIK治疗的患者纳入观察组（OG）。观察并比较两组的治疗效果、免疫功能指标、治疗前后血清肿瘤标志物、不良反应、2年生存率及治疗后6个月的生活质量。

结果

发现OG的治疗效果优于CG（P<0.05）。治疗后，OG的IgG、IgA和IgM水平显著高于CG。治疗后OG的CEA、CA724和CA199水平显著低于CG（P<0.05）。两组不良反应发生率差异无统计学意义（P>0.05）。OG治疗后6个月的生活质量和2年生存率显著高于CG（P<0.05）。逻辑回归分析显示，病理分期、分化程度和治疗方案是预后不良的独立危险因素（P<0.05）。